Mirae Asset Global Investments
CNTA

Mirae Asset Global Investments’s Centessa Pharmaceuticals CNTA Stock Holding History

Mirae Asset Global Investments’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,238
Closed -$248K – 1684
2026
Q1 		$248K Buy
6,238
+1,550
+33% +$39.6K ﹤0.01% 1048
2025
Q4 		$117K Buy
4,688
+979
+26% +$24.8K ﹤0.01% 1232
2025
Q3 		$89.9K Buy
3,709
+20
+0.5% +$355 ﹤0.01% 1235
2025
Q2 		$48.5K Buy
3,689
+634
+21% +$8.03K ﹤0.01% 1264
2025
Q1 		$44.6K Buy
3,055
+83
+3% +$1.36K ﹤0.01% 1258
2024
Q4 		$50.4K Buy
2,972
+416
+16% +$6.89K ﹤0.01% 1266
2024
Q3 		$40.4K Buy
2,556
+826
+48% +$10.1K ﹤0.01% 1338
2024
Q2 		$15.5K Buy
+1,730
New +$16.4K ﹤0.01% 1417
2022
Q3 		– Sell
-57,342
Closed -$703K – 2601
2022
Q2 		$703K Buy
+57,342
New +$367K ﹤0.01% 1588

Mirae Asset Global Investments's CNTA Position: Q2 2026 in Review

Mirae Asset Global Investments sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 6,238 shares — an estimated $248K sold.

Mirae Asset Global Investments first reported a position in CNTA in Q2 2022 and held it in 9 quarters. The position peaked at $703K in Q2 2022. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • Mirae Asset Global Investments reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mirae Asset Global Investments sold 6,238 Centessa Pharmaceuticals shares in Q2 2026, an estimated $248K.
  • Mirae Asset Global Investments first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 9 quarters.
  • Mirae Asset Global Investments's Centessa Pharmaceuticals position peaked at $703K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.